ClinicalTrials.gg
CompletedNCT03296163STELLAUpdated Apr 26, 2021Results posted

A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of MB02 (Bevacizumab Biosimilar Drug) and EU-approved Avastin® in Non-small Cell Lung Cancer, sponsored by mAbxience Research S.L.. Completed at 118 sites in 18 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-04-26.

Sponsored by mAbxience Research S.L. (part of Fresenius Kabi) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
627
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 140 studies in Carcinoma, Non-Small-Cell Lung with a site in Russian Federation — 1 open to participants now, 4 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Russian Federation.

Enrollment
40th of 132
627 · median 375
Started
2018
with 5 others
Phase 3
75 of 140
1 open now
Registered
117th of 140
by date

Among the 140 studies in Carcinoma, Non-Small-Cell Lung with a site in Russian Federation, this one is the 40th largest by enrollment of the 132 interventional ones that give a count, is one of 6 that started in 2018, is one of 75 in phase 3, and was the 117th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 140 studies in Carcinoma, Non-Small-Cell Lung with a site in Russian Federation is open now. Recruiting first, the newest first:

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 140 studies in Carcinoma, Non-Small-Cell Lung with a site in Russian Federation, or all of them as a file.
02

Study summary

This is a multicenter, multinational, double-blind, 1:1 randomized, parallel-group, equivalence Phase 3 study to compare the efficacy and safety of MB02 plus chemotherapy (carboplatin and paclitaxel) versus Avastin® plus chemotherapy (carboplatin and paclitaxel) in subjects with Stage IIIB/IV non-squamous NSCLC

Read the detailed description

Efficacy parameters, safety profiles and immunogenicity will be compared between MB02 (Bevacizumab Biosimilar Drug) and European (EU)-approved Avastin®

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and female subjects aged ≤ 18 years to ≤ 80 years.
  2. Signed must be obtained before initiation of any study-specific procedures or treatment as confirmation of the subject's awareness and willingness to comply with the study requirements.
  3. Subjects should have newly diagnosed or recurrent Stage IIIB/IV (defined by seventh edition of the Tumor, Node and (TNM) classification for Lung Cancer, 2010) non-squamous NSCLC not amenable to curative intent surgery, and not have received any systemic therapy for advanced disease (exclusion criteria 3 and 4). For subjects with recurrent disease, at least 6 months must have elapsed before randomization from previous treatment.
  4. Previous radiation therapy if completed >4 weeks before randomization. Palliative radiotherapy to bone lesions is allowed if completed >2 weeks of randomization.
  5. Subjects must have at least 1 unidimensional per version 1.1 (assessed locally).
  6. Subjects must have an (ECOG) performance status ≤1 at Screening.
  7. Subjects must have adequate hepatic, renal and hematologic function defined as:

    • Hepatic function: level \<1.5 the (ULN), (ALT) and aspartate aminotransferase (AST) levels\<2.5×ULN.
    • Renal function: serum creatinine level \<1.5×ULN, calculated (CrCl) >50 mL/min (Cockcroft-Gault formula), urine protein to creatinine ratio \<1. Subjects with urine protein-to-creatinine ratio >1 may be enrolled if they have \<1 g of protein in 24-hour urine collection.
    • Hematological function: >1.5×109 /L; >100×109 /L, (Hb) >9 g/dL.
    • Adequate coagulation parameters such as: ≤ 2.0 and aPTT ≤ 1.5 x ULN within 7 days prior to randomization for patients not receiving anticoagulation therapy.
  8. Eligible subjects must have a systolic blood pressure of ≤ 140 mm Hg and a diastolic blood pressure of ≤90 mm Hg at screening.
  9. Women of , and their partners, must agree to adhere to pregnancy prevention methods throughout the duration of the study (including the Follow-up visits, where applicable). Women of childbearing potential are defined as those who are not surgically sterile (did not underwent bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) and not .

Subjects and their partners must agree to use a highly effective method of , to avoid women becoming pregnant throughout the course of the study. Medically acceptable forms of birth control can include the following, with approval of the treating physician:

  • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence.

    1. Non fertile women can be included, that is, those who are physiologically incapable of becoming pregnant, because of:
  • Hysterectomy.
  • Bilateral oophorectomy (ovariectomy).
  • Bilateral tubal ligation or,
  • Postmenopausal women defined as:

Subjects not using hormone replacement therapy (HRT) and have experienced total cessation of menses for ≥ 1 year and be greater than 45 years of age, OR, in questionable cases, have a follicle stimulating hormone >40 mIU/mL and an estradiol value \<40 pg/mL (\<140 pmol/L).

Subjects must discontinue HRT before study enrolment because of the potential for inhibition of cytochrome enzymes that metabolize estrogens and progestins. For most forms of HRT, at least 2 to 4 weeks must elapse between the cessation of HRT and determination of menopausal status; the length of this interval depends on the type and dosage of HRT.

If a female subject is determined not to be postmenopausal, that subject must use adequate contraception, as defined immediately above (inclusion 8).

Exclusion criteria

Exclusion Criteria:

  1. Inability to comply with protocol procedures.
  2. Participation in another clinical trial or treatment with another agent within 4 weeks or 5 half-lives of investigational agent before randomization, whichever is longer.
  3. Subjects previously treated with monoclonal antibodies or small molecule inhibitors against Vascular Endothelial Growth Factor (VEGF) or VEGF receptors, including Avastin®.
  4. Subjects who have received previous chemotherapy, immunotherapy, targeted therapy, or biological therapy for their lung cancer. Note: and neo- adjuvant therapy are permitted (see: inclusion criterion 3).
  5. Subjects who have known central nervous system disease, with the exception of subjects with treated who have completed treatment (radiation, surgery or stereotactic surgery) and have not received for at least 4 weeks before randomization. Subjects with central nervous system treated by neurosurgical resection or brain performed within 8 weeks before randomization will be excluded. Subjects with known or history of brain metastases must undergo brain imaging during screening.
  6. Current or recent (within 10 days of the first dose of study treatment) use of aspirin (at least 325 mg/day) or other nonsteroidal anti-inflammatory drugs with antiplatelet activity or treatment with dipyridamole (Persantine®), ticlopidine (Ticlid®), clopidogrel (Plavix®), or cilostazol (Pletal®).
  7. Current or recent (within 5 days) use of therapeutic anticoagulation or use of thrombolytic agent. Prophylactic use of low molecular weight heparin is allowed.
  8. Subjects with an >2, unless receiving active anticoagulation treatment, will be excluded.
  9. Subjects who have a diagnosis of small cell carcinoma of the lung or squamous cell carcinoma of the lung. Mixed tumors should be categorized according to the predominant histology. If small cell elements are present, the subject will be excluded.
  10. Subjects with known tumors that harbor activating epidermal growth factor receptor and anaplastic lymphoma receptor tyrosine kinase (assessed locally).
  11. Subjects who have a history of to the active substance (bevacizumab, carboplatin, and/or paclitaxel) or any of the (such as trehalose dehydrate, sodium phosphate, or polysorbate 20).
  12. Subjects with known active viral infection, including but not limited to: , , or .
  13. Subjects who are pregnant or breastfeeding. Women of must have a negative pregnancy test at Screening.
  14. Subjects with previous major surgery, open biopsy, open pleurodesis, or significant traumatic injury within 4 weeks before randomization or those anticipated to require major surgery during the study.
  15. Subjects who have had a core biopsy taken or have had another minor surgical procedure, excluding placement of vascular access device, closed pleurodesis, thoracentesis, and mediastinoscopy, within 1 week of randomization.
  16. Subjects with a history of abdominal fistula, GI perforation, intra-abdominal abscess within 6 months of randomization.
  17. Subjects with a nonhealing wound, active ulcer, or untreated bone fracture.
  18. Subjects with previous history of hypertensive crisis or hypertensive encephalopathy.
  19. Subjects with Grade II or greater congestive heart failure, or angina, myocardial infarction within 6 months before randomization; symptomatic arrhythmia or serious cardiac arrhythmia requiring medication; abnormal \< 50% assessed by ultrasound or multigated acquisition scan.
  20. Subjects with a previous within 3 years of randomization (other than superficial basal cell and superficial squamous (skin) cell carcinoma, or carcinoma in situ of the uterine cervix, bladder, or prostate).
  21. Subjects with history of a significant vascular event within 6 months before randomization (including, but not limited to myocardial infarction and stroke or ).
  22. Subjects with known bleeding diathesis or significant coagulopathy defined as a bleeding event grade ≥ 2 within 3 months before randomization.
  23. Subjects with history of grade ≥2 hemoptysis within 6 months before randomization (≥0.5 teaspoons of bright red blood per event).
  24. Subjects with a tumor(s) invading or compressing major blood vessels.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
627 participants (actual)

Study arms

  • Experimental
    MB02 (Bevacizumab Biosimilar Drug)

    MB02 (Bevacizumab Biosimilar Drug) + Carboplatin/Paclitaxel

    Drug: MB02 (Bevacizumab Biosimilar Drug) · Drug: Carboplatin · Drug: Paclitaxel

  • Active comparator
    EU-approved Avastin®

    EU-approved Avastin® + Carboplatin/Paclitaxel

    Drug: EU-approved Avastin® · Drug: Carboplatin · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) at Week 18

    Objective response rate was assigned for a subject if the subject displayed either complete response (CR) or partial response (PR) per RECIST version 1.1 at Week 18, as assessed by independent radiological review committee (IRC). Overall Response (OR) = CR + PR.

    Time frame: 18 weeks from randomisation

Secondary outcomes

  1. Progression-free Survival (PFS)

    Progression-free survival was defined as the time from randomization to subsequent confirmed progression per RECIST version 1.1, or death (whichever occurred first), measured in weeks and months. For PFS assessment clinical progression (i.e., treatment discontinuation due to progression of disease) was also considered as an event.

    Time frame: At Week 52 from randomisation

  2. Overall Survival (OS)

    Overall survival was defined as the time from randomization to subsequent death, measured in weeks and months.

    Time frame: At Week 52 from randomisation

  3. Incidence of Treatment-emergent Adverse Events (TEAEs)

    Comparison of Safety profile. Safety was monitored by incidence of adverse events (AEs). AEs were coded as per MedDRA (version 20.1) and severity was graded according to NCI-CTCAE (version 4.03);

    Time frame: Week 1 to week 52

  4. Immunogenicity Assessments (Anti-drug Antibodies [ADA] and Neutralizing Antibodies [NAb])

    Incidence of anti-drug antibodies (ADA) and neutralizing ADAs (NAb). Analyses of ADA incidence rate, antibody titer, and neutralizing antibodies (NAb) (following the recommended 3-tier approach) were performed.

    Time frame: At Weeks 1, 4, 10, 19, 34 and 52 from randomization and, at the End of Treatment Visit if, an ADA sample has not been collected within the previous 3 weeks

07

Results

Posted Mar 26, 2021

Participant flow

Combination Therapy
Participant flow — Combination Therapy
MilestoneMB02 (Bevacizumab Biosimilar Drug)EU-approved Avastin®
Started315312
Completed207220
Not completed10892
Monotherapy
Participant flow — Monotherapy
MilestoneMB02 (Bevacizumab Biosimilar Drug)EU-approved Avastin®
Started207220
Completed6874
Not completed139146

Outcome measures

PrimaryObjective Response Rate (ORR) at Week 18

Objective response rate was assigned for a subject if the subject displayed either complete response (CR) or partial response (PR) per RECIST version 1.1 at Week 18, as assessed by independent radiological review committee (IRC). Overall Response (OR) = CR + PR.

Time frame:
18 weeks from randomisation
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) at Week 18
Percentage of participantsMB02 (Bevacizumab Biosimilar Drug)EU-approved Avastin®
Objective Response Rate (ORR) at Week 1840.3 (34.9 to 46.0)44.6 (39.0 to 50.3)
Statistical analysis
  • MB02 (Bevacizumab Biosimilar Drug) vs EU-approved Avastin® · Risk ratio (rr): 0.910 · 90% CI 0.780 to 1.060Direction of comparison is: For RR: MB02/EU-approved Avastin. 95% CI was also calculated: (0.758, 1.092)
  • MB02 (Bevacizumab Biosimilar Drug) vs EU-approved Avastin® · Risk difference (rd): -4.02 · 90% CI -10.51 to 2.47Direction of comparison is: For RD: MB02 - EU-approved Avastin. 95% CI was also calculated: (-11.76, 3.71)
SecondaryProgression-free Survival (PFS)

Progression-free survival was defined as the time from randomization to subsequent confirmed progression per RECIST version 1.1, or death (whichever occurred first), measured in weeks and months. For PFS assessment clinical progression (i.e., treatment discontinuation due to progression of disease) was also considered as an event.

Time frame:
At Week 52 from randomisation
Reported as:
Median · weeks
Progression-free Survival (PFS)
weeksMB02 (Bevacizumab Biosimilar Drug)EU-approved Avastin®
Progression-free Survival (PFS)36.0 (33.0 to 36.43)37.3 (36.14 to 45.14)
Statistical analysis
  • MB02 (Bevacizumab Biosimilar Drug) vs EU-approved Avastin® · Hazard ratio (hr): 1.187 · 95% CI 0.98 to 1.44
SecondaryOverall Survival (OS)

Overall survival was defined as the time from randomization to subsequent death, measured in weeks and months.

Time frame:
At Week 52 from randomisation
Reported as:
Median · weeks
Overall Survival (OS)
weeksMB02 (Bevacizumab Biosimilar Drug)EU-approved Avastin®
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • MB02 (Bevacizumab Biosimilar Drug) vs EU-approved Avastin® · Hazard ratio (hr): 1.108 · 95% CI 0.827 to 1.485
SecondaryIncidence of Treatment-emergent Adverse Events (TEAEs)

Comparison of Safety profile. Safety was monitored by incidence of adverse events (AEs). AEs were coded as per MedDRA (version 20.1) and severity was graded according to NCI-CTCAE (version 4.03);

Time frame:
Week 1 to week 52
Reported as:
Number · participants
Incidence of Treatment-emergent Adverse Events (TEAEs)
participantsMB02 (Bevacizumab Biosimilar Drug)EU-approved Avastin®
with ≥1 TEAE288288
with ≥1 Grade 3 or 4 TEAE131125
with ≥1 treatment-related TEAE264270
with ≥1 Grade 3 or 4 treatment-related TEAE9891
with at least one Serious TEAE5854
with ≥1 TEAE leading to discontinuation7263
with ≥1 treatment-related TEAE leading to discontinuation4233
SecondaryImmunogenicity Assessments (Anti-drug Antibodies [ADA] and Neutralizing Antibodies [NAb])

Incidence of anti-drug antibodies (ADA) and neutralizing ADAs (NAb). Analyses of ADA incidence rate, antibody titer, and neutralizing antibodies (NAb) (following the recommended 3-tier approach) were performed.

Time frame:
At Weeks 1, 4, 10, 19, 34 and 52 from randomization and, at the End of Treatment Visit if, an ADA sample has not been collected within the previous 3 weeks
Reported as:
Number · participants
Immunogenicity Assessments (Anti-drug Antibodies [ADA] and Neutralizing Antibodies [NAb])
participantsMB02 (Bevacizumab Biosimilar Drug)EU-approved Avastin®
ADA positive5350
NAb positive1013
NO seroconversion239247

Adverse events

Collected over Throughout the study completion. An average of two years (from the beginning of the study at 06-February-2018 till last patient last visit in 27-February-2020).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MB02 (Bevacizumab Biosimilar Drug)23/311 (7.4%)58/311 (18.6%)288/311 (92.6%)
EU-approved Avastin®24/310 (7.7%)54/310 (17.4%)288/310 (92.9%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventMB02 (Bevacizumab Biosimilar Drug)EU-approved Avastin®
PneumoniaInfections and infestations8/3118/310
Febrile neutropeniaBlood and lymphatic system disorders4/3117/310
NeutropeniaBlood and lymphatic system disorders3/3116/310
General physical health deteriorationGeneral disorders3/3116/310
Pulmonary embolismRespiratory, thoracic and mediastinal disorders6/3114/310
EmpyemaInfections and infestations3/3110/310
GastroenteritisInfections and infestations1/3112/310
AnemiaBlood and lymphatic system disorders1/3112/310
AstheniaGeneral disorders0/3112/310
FatigueGeneral disorders0/3112/310
Most frequent other events
Showing 10 of 26
Most frequent other events
EventMB02 (Bevacizumab Biosimilar Drug)EU-approved Avastin®
AlopeciaSkin and subcutaneous tissue disorders155/311163/310
AnemiaBlood and lymphatic system disorders101/31194/310
NauseaGastrointestinal disorders47/31144/310
NeutropeniaBlood and lymphatic system disorders34/31145/310
ThrombocytopeniaBlood and lymphatic system disorders41/31142/310
Neuropathy peripheralNervous system disorders38/31141/310
FatigueGeneral disorders39/31136/310
AstheniaGeneral disorders39/31129/310
MyalgiaMusculoskeletal and connective tissue disorders23/31130/310
General physical health deteriorationGeneral disorders23/31129/310

Baseline characteristics

Age, Continuous
Age, Continuous(years)MB02 (Bevacizumab Biosimilar Drug)EU-approved Avastin®Total
Median61.0 (54.0 to 67.0)61.0 (56.0 to 67.5)61.0 (55.0 to 67.0)
Sex: Female, Male
Sex: Female, Male(Participants)MB02 (Bevacizumab Biosimilar Drug)EU-approved Avastin®Total
Female122122244
Male193190383
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MB02 (Bevacizumab Biosimilar Drug)EU-approved Avastin®Total
American Indian or Alaska Native000
Asian7154125
Native Hawaiian or Other Pacific Islander000
Black or African American112
White243256499
More than one race000
Unknown or Not Reported011
Body surface area (BSA)
Body surface area (BSA)(m^2)MB02 (Bevacizumab Biosimilar Drug)EU-approved Avastin®Total
Median1.780 (1.600 to 1.940)1.790 (1.595 to 1.940)1.780 (1.600 to 1.940)
08

Study locations

118 sites
  • MedRadius
    Maceió, AL, Brazil
  • Instituto do Câncer do Ceará - ICC
    Fortaleza, CE, Brazil
  • Centro Brasileiro de Radioterapia Oncologia e Mastologia
    Goiânia, GO, Brazil
  • Hospital Erasto Gaertner - Paranaense de Combate ao Câncer
    Curitiba, PR, Brazil
  • Instituto Nacional de Cancer- INCA
    Rio de Janeiro, RJ, Brazil
  • Centro de Pesquisa e Educação da Serra Gaúcha (CEPESG)
    Caxias do Sul, RS, Brazil
  • IPCEM Universidade de Caxias Do Sul
    Caxias do Sul, RS, Brazil
  • Hospital de Caridade de Ijuí
    Ijuí, RS, Brazil
  • Instituto do Câncer - Hospital São Vicente de Paulo
    Passo Fundo, RS, Brazil
  • Hospital São Lucas da PUCRS
    Pôrto Alegre, RS, Brazil
  • Hospital de Câncer de Barretos
    Barretos, SP, Brazil
  • Hospital de Base de São José do Rio Preto
    São José do Rio Prêto, SP, Brazil
  • Centro de Pesquisa do Instituto Brasileiro de Controle do Câncer - IBCC
    São Paulo, SP, Brazil
  • Instituto de Ensino e Pesquisa São Lucas
    São Paulo, SP, Brazil
  • Hospital Santa Marcelina
    Sao Paulo, Brazil
  • Central Hospital Plovdiv
    Plovdiv, Bulgaria
  • Acıbadem City Clinic Cancer Center UMHAT
    Sofia, Bulgaria
  • Specialized Hospital for Active Treatment of Oncology Diseases Sofia District EOOD
    Sofia, Bulgaria
  • Fundación Arturo López Pérez - Instituto Oncológico FALP
    Santiago, Chile
  • Health & Care Spa
    Santiago, Chile
  • Instituto Clinico Oncologico del Sur ICOS
    Temuco, Chile
  • Oncocentro APYS
    Viña del Mar, Chile
  • Cancer Center of Adjara Autonomous Republic
    Batumi, Georgia
  • Acad. F . Todua medical center-research institute of clinical medicine
    Tbilisi, Georgia
  • Consilium Medulla
    Tbilisi, Georgia
  • Institute of Clinical Oncology
    Tbilisi, Georgia
  • LTD Aversi Clinic
    Tbilisi, Georgia
  • LTD Cancer Research Centre
    Tbilisi, Georgia
  • Tbilisi State Medical Universitys First university Clinic
    Tbilisi, Georgia
  • General Hospital of Athens "Ippokratio"
    Athens, Greece
  • Sotiria General Hospital for Chest Diseases
    Athens, Greece
  • University General Hospital of Larissa
    Lárisa, Greece
  • Agioi Anargyroi General Oncological Hospital of Kifissia
    Néa Kifisiá, Greece
  • General Hospital of Thessaloniki "George Papanikolaou"
    Thessaloníki, Greece
  • National Koranyi Institute of TB and Pulmonology
    Budapest, Hungary
  • Országos Korányi Pulmonológiai Intézet (OKPI)
    Budapest, Hungary
  • Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkórháza
    Deszk, Hungary
  • Veszprém Megyei Tüdőgyógyinzézet
    Farkasgyepű, Hungary
  • Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház
    Miskolc, Hungary
  • Zydus Hospital
    Ahmedabad, India
  • Action Cancer Hospital
    Delhi, India
  • Aadhar Health Institute
    Hisar, India
  • NIMS - Nizam's Institute of Medical Sciences
    Hyderabad, India
  • Ganadhipati Purushottam Shekhawati Hospital Research Centre
    Jaipur, India
  • PVS Hospital Pvt Ltd
    Kerola, India
  • Apollo Gleneagles Hospital
    Kolkata, India
  • Netaji Subhas Chandra Bose Cancer Research Institute
    Kolkata, India
  • Shatabdi Super Speciality Hospital
    Nashik, India
  • Deenanath Mangeshkar Hospital & Research Center
    Pune, India
  • Nirmal Hospital Pvt. Ltd.
    Surat, India
  • Kiran Super Multispeciality Hospital
    Sūrat, India
  • Shree Himalaya Cancer Hospital Research Institute
    Vadodara, India
  • Queen's NRI Hospital Gurudwara Lane
    Visakhapatnam, India
  • Notre Dame de Secours
    Jbaïl, Lebanon
  • Hospital Pulau Pinang
    George Town, Pulau Pinang, Malaysia
  • Institut Perubatan dan Pergigian Termaju Universiti Sains Malaysia
    Kepala Batas, Malaysia
  • Hospital Kuala Lumpur
    Kuala Lumpur, Malaysia
  • Pusat Perubatan Universiti Kebangsaan Malaysia
    Kuala Lumpur, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, Malaysia
  • Hospital Umum Sarawak
    Kuching, Malaysia
  • National Cancer Institute
    Putrajaya, Malaysia
  • Instituto Nacional de Cancerologia
    Mexico City, Mexico
  • Hospital Universitario Dr. Jose Eleuterio González
    Monterrey, Mexico
  • Sultan Qaboos University Hospital
    Muscat, Oman
  • Baguio General Hospital & Medical Center
    Baguio, Philippines
  • Cebu Doctors University Hospital - CDUH
    Cebu, Philippines
  • Perpetual Succour Hospital - PSH
    Cebu, Philippines
  • De La Salle University Medical Center - DLSUMC
    Dasmariñas, Philippines
  • Davao Doctors Hospital - DDH
    Davao, Philippines
  • Makati Medical Center
    Makati City, Philippines
  • Philippine General Hospital - PGH
    Manila, Philippines
  • The Medical City
    Pasig, Philippines
  • St. Luke's Medical Center - Global City
    Taguig, Philippines
  • SBHI Arkhangelsk Region - Arkhangelsk Clinical Oncological Dispensary
    Arkhangel'sk, Russian Federation
  • Regional state budgetary Healthcare Institution "Belgorod oncology dispensary"
    Belgorod, Russian Federation
  • State Budget Healthcare Institution Ivanovo Regional Oncology Dispensary
    Ivanovo, Russian Federation
  • Kaluga Regional Clinical Oncology center
    Kaluga, Russian Federation
  • Republic Clinical Oncology Dispensary
    Kazan', Russian Federation
  • Kursk Republican Clinical Oncology Dispensary
    Kursk, Russian Federation
  • "VitaMed" LLC
    Moscow, Russian Federation
  • Moscow City Oncology Hospital No 62
    Moscow, Russian Federation
  • N. N. Blokhin Russian Cancer Research Center
    Moscow, Russian Federation
  • University Headache Clinic LLC
    Moscow, Russian Federation
  • Federal budget Healthcare Institution "Volga District Medical Centre" under Federal Medical and Biological Agency
    Novgorod, Russian Federation
  • GBUZ of SK Pyatigorsk Oncology Dispensary
    Pyatigorsk, Russian Federation
  • Ryazan Regional Clinical Oncology Dispensary
    Ryazan', Russian Federation
  • City Clinical Oncology Dispensary
    Saint Petersburg, Russian Federation
  • GUZ "Leningrad Regional Clinical Hospital"
    Saint Petersburg, Russian Federation
  • State Budgetary healthcare Institution "Samara regional clinical oncology dispensary"
    Samara, Russian Federation
  • CHC Bezanijska Kosa
    Belgrade, Serbia
  • Institute of Oncology and Radiology of Serbia (IORS)
    Belgrade, Serbia
  • Clinical Center Kragujevac
    Kragujevac, Serbia
  • Clinical center Nis (Clinic for pulmonary diseases)
    Niš, Serbia
  • Institute for Pulmonary Diseases of Vojvodina
    Sremska Kamenica, Serbia
  • Hospital Universitario Puerta de Hierro Majadahonda
    Madrid, Spain
  • Bangkok International Hospital And Wattanosod Hospital
    Bangkok, Thailand
  • Chiang Mai University (CMU) - Maharaj Nakhon Chiang Mai Hospital Nakorn Chiang Mai Hospital
    Chiang Mai, Thailand
  • Chiang Rai Prachanukroh Hospital
    Chiang Rai, Thailand
  • Songklanagarind Hospital
    Hat Yai, Thailand
  • Buddhachinaraj Hospital
    Phitsanulok, Thailand

Showing the first 100 of 118 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Trukhin D, Poddubskaya E, Andric Z, Makharadze T, Bellala RS, Charoentum C, Yanez Ruiz EP, Fulop A, Hyder Ali IA, Syrigos K, Katgi N, Lopez Chuken YA, Rumyana I, Reyes-Igama J, Costamilan RC, Del Campo Garcia A, Florez A, Paravisini A, Millan S; STELLA Investigators. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA). BioDrugs. 2021 Jul;35(4):429-444. doi: 10.1007/s40259-021-00483-w. Epub 2021 Apr 29. PubMed 33914256 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Jul 2019, 16 months.

Results were first posted in Mar 2021, 1 year 8 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 16 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2017
First posted
Sep 28, 2017
StartActual
Feb 6, 2018
Primary completionActual
Jul 3, 2019
CompletionActual
Feb 27, 2020
Results first posted
Mar 26, 2021
Last update
Apr 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03296163
Responsible party
Sponsor
First posted
Sep 28, 2017
Start date
Feb 6, 2018
Primary completion
Jul 3, 2019
Completion
Feb 27, 2020
Results posted
Mar 26, 2021
Last update
Apr 26, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MB02

Start the discussion